FIA
KRBP

FNY Investment Advisers’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

FNY Investment Advisers’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$288K – 1003
2021
Q2 		$288K Buy
+2,000
New +$501K 0.12% 152

Other funds holding KRBP

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FNY Investment Advisers's KRBP Position: Q3 2021 in Review

FNY Investment Advisers sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q3 2021, closing a stake of 2,000 shares — an estimated $288K sold.

FNY Investment Advisers first reported a position in KRBP in Q2 2021 and held it in 1 quarter. The position peaked at $288K in Q2 2021. 23 funds tracked by Wall St. Rank hold KRBP as of Q3 2021.

  • FNY Investment Advisers reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 2,000 Kiromic BioPharma, Inc. Common Stock shares in Q3 2021, an estimated $288K.
  • FNY Investment Advisers first reported a position in Kiromic BioPharma, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • FNY Investment Advisers's Kiromic BioPharma, Inc. Common Stock position peaked at $288K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q3 2021.

Based on FNY Investment Advisers's 13F filing for Q3 2021, filed 13 Oct 2021.